Bevacizumab (TBD) mCRC NSCLC Biosimilar – Details


( Last Updated : June 17, 2019)
Generic Name:
Bevacizumab
Project Status:
Cancelled
Manufacturer:
Pfizer Canada Inc.
Brand Name:
TBD
Project Line:
Reimbursement Review
Project Number:
PC0178-000

Details


Tumour Type:
Gastrointestinal / Lung
Indications:
Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer Biosimilar
Funding Request:
Metastatic Colorectal Cancer (mCRC); Non-Small Cell Lung Cancer (NSCLC)
Review Status:
Cancelled
Pre Noc Submission:
Yes
Sponsor:
Pfizer Canada Inc.
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.